GS
TGTX icon

GTS Securities’s TG Therapeutics TGTX Stock Holding History

GTS Securities’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80,400
Closed -$1.88M – 3824
2024
Q3 		$1.88M Sell
80,400
-39,300
-33% -$858K ﹤0.01% 1610
2024
Q2 		$2.13M Sell
119,700
-38,000
-24% -$606K ﹤0.01% 1454
2024
Q1 		$2.4M Buy
157,700
+27,700
+21% +$441K ﹤0.01% 1368
2023
Q4 		$2.22M Buy
130,000
+21,700
+20% +$252K ﹤0.01% 1583
2023
Q3 		$905K Buy
+108,300
New +$1.51M ﹤0.01% 2094

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GTS Securities's TGTX Position: Q1 2026 in Review

GTS Securities opened a new position in TG Therapeutics (TGTX) in Q1 2026: 7,139 shares worth $237K. The stake represents 0.01% of the portfolio and ranks #1250 among its holdings. This is a return to the name: GTS Securities previously reported a position in TGTX as recently as Q3 2024.

GTS Securities first reported a position in TGTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $7.02M in Q4 2023. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • GTS Securities held 7,139 shares of TG Therapeutics worth $237K as of Q1 2026.
  • TG Therapeutics was a new GTS Securities position in Q1 2026.
  • TG Therapeutics made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1250 holding.
  • GTS Securities first reported a position in TG Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • GTS Securities's TG Therapeutics position peaked at $7.02M in Q4 2023.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.